SPECIAL NOTICE
A -- Evaluation of Synergistic Activities & Efficacy of Combination Drug Theropy in Treatment of Multi-Drug Resistant Inhilation Anthrax in Murine Model
- Notice Date
- 7/29/2011
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2011-N-13559
- Archive Date
- 8/27/2011
- Point of Contact
- Gary L. Morgan, Phone: (770) 488-2639, Jeff A Miller, Phone: 770-488-2651
- E-Mail Address
-
glm5@cdc.gov, afx2@cdc.gov
(glm5@cdc.gov, afx2@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC) intends to award, on a sole source basis, a firm fixed price contract to the University of Florida fot an Evaluation of Synergistic activities and efficacy of combination drug theropy for early treatment of multi-drug resistant (MDR) inhalation anthrax in murine model. This acquisition for an in vivo research study using the mouse model to evaluate the therapeutic benefit and synergistic activity of various antimicrobial agent combinations for the treatment of inhalation anthrax resulting from exposure to a Bacillus anthracis strain that is resistant to the first-line antimicrobial treatment agent ciprofloxacin. This research study will address the CDC and HHS priority for multidrug resistant (MDR) organisms with potential for bioterrorist use as identified in the HHS Strategy and Implementation Plan for chemical, biological, radiological, and nuclear (CBRN) threats. This study will also provide data addressing Homeland Security Presidential Directive 18 which calls for development of the capacity to address enhanced biological threat agents, including MDR Bacillus anthracis strains resistant to the first-line recommended antimicrobial agents ciprofloxacin and doxycycline. Justification for other than full and open competition is considered due to the fact that University of Florida is proposed as the contractor for this study. The Senior Scientist at University of Florida is Dr. Henry Heine, who provides University of Florida with unique and extensive experience using the mouse Bacillus anthracis aerosolized spore challenge model - which was selected for use in this study - as the principle investigator for the development and validation of this animal research model (Antimicrob Agents Chemother. 2007; 51(4):1373-9), and who has published as lead investigator multiple studies testing the efficacy of drugs used for the prophylaxis and treatment of inhalation anthrax in this research model. Dr. Heine at University of Florida has available existing published and unpublished research data from previous studies on the pharmacokinetics of those antimicrobial drugs and on their optimization in the mouse model, and many of those drugs will be tested in this project. This will eliminate the need for the conduct of preliminary single-drug pharmacokinetic studies on these drugs to enable comparison with the multidrug antimicrobial agent combination pharmacokinetic studies, which will be necessary to measure any impact of the use in the multidrug regimens on the pharmacokinetics of the individual component drugs. Note 22 applies herein. The NAICS code for this requirement is 541712. The statutory authority permitting other-than-full-and-open competition is 41 U.S.C., 253(c)(1): FAR 6.302-1. Only one responsible source and no other services will satisfy agency requirements. Interested persons may identify their interest and capability to respond to the requirement. This notice is not a request for competitive proposals. A determination by the Government not to compete this proposed contract will be based on responses to this notice and is solely within the discretion of the government. Information received will be considered solely for informational purposes. This procurement is not set-aside for small business. Please note that an award will be issued to a vendor who is registered and validated in CCR and has a DUNS number. All inquiries must be clearly marked on the subject line of the e-mail (Reference #95741). This procurement is not set-aside for small business. For contractual questions contact Gary Morgan by email at glm1@CDC.gov, no phone calls will be addressed. All concerns should be e-mailed.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2011-N-13559/listing.html)
- Place of Performance
- Address: Atlanta, Georgia, Atlanta, Georgia, 30034, United States
- Zip Code: 30034
- Zip Code: 30034
- Record
- SN02515865-W 20110731/110729235440-8f25fb6cbbe66231eb939bd00688be00 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |